 COPENHAGEN, Denmark, September 24, 2021 Bavarian Nordic AS OMX: BAVA announced today that the funding agreement recently entered with the Danish Ministry of Health to further advance the development of ABNCoV2, the Companys COVID-19 vaccine candidate, has now been approved by the Finance Committee of the Danish Parliament, thereby finally executing the agreement. 